CD209 and metabolic dysfunction-associated steatotic liver disease: As liver steatosis, inflammation, and fibrosis are hallmarks of NAFLD/NASH, and since injections of a CD209 ligand and DANA both inhibit inflammation and fibrosis, we examined whether injections of DANA or a CD209 ligand could inhibit MCD diet-induced liver inflammation and steatosis and adipose tissue loss in mice.